Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C21H17FN2O2 |
| Molecular Weight | 348.3703 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=C(CC2=NC3=C(C=CC=C3)C=C2)C4=C(C=CC(F)=C4)N1CC(O)=O
InChI
InChIKey=FATGTHLOZSXOBC-UHFFFAOYSA-N
InChI=1S/C21H17FN2O2/c1-13-17(11-16-8-6-14-4-2-3-5-19(14)23-16)18-10-15(22)7-9-20(18)24(13)12-21(25)26/h2-10H,11-12H2,1H3,(H,25,26)
| Molecular Formula | C21H17FN2O2 |
| Molecular Weight | 348.3703 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 04:36:09 UTC 2023
by
admin
on
Sat Dec 16 04:36:09 UTC 2023
|
| Record UNII |
04XB9TB8OL
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C574
Created by
admin on Sat Dec 16 04:36:09 UTC 2023 , Edited by admin on Sat Dec 16 04:36:09 UTC 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
CHEMBL560993
Created by
admin on Sat Dec 16 04:36:09 UTC 2023 , Edited by admin on Sat Dec 16 04:36:09 UTC 2023
|
PRIMARY | |||
|
300000008740
Created by
admin on Sat Dec 16 04:36:09 UTC 2023 , Edited by admin on Sat Dec 16 04:36:09 UTC 2023
|
PRIMARY | |||
|
C152633
Created by
admin on Sat Dec 16 04:36:09 UTC 2023 , Edited by admin on Sat Dec 16 04:36:09 UTC 2023
|
PRIMARY | |||
|
DB11900
Created by
admin on Sat Dec 16 04:36:09 UTC 2023 , Edited by admin on Sat Dec 16 04:36:09 UTC 2023
|
PRIMARY | |||
|
851723-84-7
Created by
admin on Sat Dec 16 04:36:09 UTC 2023 , Edited by admin on Sat Dec 16 04:36:09 UTC 2023
|
PRIMARY | |||
|
04XB9TB8OL
Created by
admin on Sat Dec 16 04:36:09 UTC 2023 , Edited by admin on Sat Dec 16 04:36:09 UTC 2023
|
PRIMARY | |||
|
DTXSID00234343
Created by
admin on Sat Dec 16 04:36:09 UTC 2023 , Edited by admin on Sat Dec 16 04:36:09 UTC 2023
|
PRIMARY | |||
|
10483
Created by
admin on Sat Dec 16 04:36:09 UTC 2023 , Edited by admin on Sat Dec 16 04:36:09 UTC 2023
|
PRIMARY | |||
|
11462174
Created by
admin on Sat Dec 16 04:36:09 UTC 2023 , Edited by admin on Sat Dec 16 04:36:09 UTC 2023
|
PRIMARY | |||
|
1422181-22-3
Created by
admin on Sat Dec 16 04:36:09 UTC 2023 , Edited by admin on Sat Dec 16 04:36:09 UTC 2023
|
NO STRUCTURE GIVEN |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
A post hoc analysis revealed that the greatest improvement of lung function by timapiprant was observed in patients with active eosinophilia (≥250/μl peripheral blood) and—even more pronounced—in younger patients (90). This applies also for the humanized murine IL-5 antibody mepolizumab, which is most effective and only given in asthma patients with severe eosinophilic airway inflammation (91). In eosinophil esophagitis, timapiprant significantly reduced the esophageal eosinophil load and induced some clinical improvement (92). Timapiprant also successfully reduced nasal and ocular symptoms in allergic subjects exposed to grass pollen (93).
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
